to proteinase 3 (PR3). Among European populations, prevalence ranges from 24 to 157 cases per million, with the highest prevalence reported in Sweden and the UK MPA is characterized histologically by vasculitis without granulomatous inflammation. Common clinical manifestations include rapidly progressive pauci-immune glomerulonephritis and alveolar hemorrhage. MPA is most commonly associated with perinuclear ANCA and antibodies to myeloperoxidase. The prevalence of MPA ranges from 0 to 66 cases